ONC in the 13F filings
Beone Medicines LTD · CUSIP 07725L102
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 8 May 2026
- Managers listing it
- 27
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 8 listed it in both
- Shares listed
- 8,123,753
- combined, among listed positions
- Reported value
- $2.4bn
- combined, at the quarter end
1 line marked †. Value as filed implies a price far from other filers'. Each counts in holders and value as filed, and is left out of the net change in shares.
Among the 91 comparable managers: 19 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +1,314,033.
Managers listing ONC in Q1 2026
27 of 27 holders
Largest increases and reductions, by shares
Increases
- Capital World Investorsnew position · 1,622,687 shares now+1,622,687
- Citadel Advisors LLCexisting position · 1,032,298 shares now+498,781
- Millennium Management LLCexisting position · 204,846 shares now+173,395
- Jane Street Group LLCnew position · 75,953 shares now+75,953
- Renaissance Technologies LLCnew position · 65,456 shares now+65,456
Reductions
- T. Rowe Price Associates Incexisting position · 539,769 shares now-832,910
- Fidelity (FMR LLC)existing position · 3,693,610 shares now-299,017
- Voloridge Investment Management LLCexisting position · 1,614 shares now-34,925
- Artisan Partners LPexisting position · 137,216 shares now-28,025
- ExodusPoint Capital Management LPexisting position · 10,980 shares now-13,604
New positions and exits
New (7)
Exited (1)
- Woodline Partners LPwas $20m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2016 | 2 | $3.0m | n.a. | n.a. |
| Q2 2016 | 1 | $2.0m | n.a. | n.a. |
| Q3 2016 | 1 | $2.1m | n.a. | n.a. |
| Q4 2016 | 1 | $2.1m | n.a. | n.a. |
| Q1 2017 | 1 | $2.6m | n.a. | n.a. |
| Q2 2017 | 1 | $3.3m | n.a. | n.a. |
| Q3 2017 | 4 | $812m | n.a. | n.a. |
| Q4 2017 | 3 | $822m | n.a. | n.a. |
| Q1 2018 | 7 | $2.0bn | n.a. | n.a. |
| Q2 2018 | 8 | $1.7bn | n.a. | n.a. |
| Q3 2018 | 9 | $2.1bn | n.a. | n.a. |
| Q4 2018 | 5 | $1.3bn | n.a. | n.a. |
| Q1 2019 | 3 | $1.1bn | n.a. | n.a. |
| Q2 2019 | 4 | $1.0bn | n.a. | n.a. |
| Q3 2019 | 3 | $1.1bn | n.a. | n.a. |
| Q4 2019 | 4 | $1.3bn | n.a. | n.a. |
| Q1 2020 | 3 | $993m | n.a. | n.a. |
| Q2 2020 | 5 | $1.7bn | n.a. | n.a. |
| Q3 2020 | 5 | $2.9bn | n.a. | n.a. |
| Q4 2020 | 9 | $2.9bn | n.a. | n.a. |
| Q1 2021 | 9 | $4.7bn | n.a. | n.a. |
| Q2 2021 | 9 | $4.2bn | n.a. | n.a. |
| Q3 2021 | 6 | $4.4bn | n.a. | n.a. |
| Q4 2021 | 6 | $3.2bn | n.a. | n.a. |
| Q1 2022 | 4 | $2.0bn | n.a. | n.a. |
| Q2 2022 | 4 | $1.5bn | n.a. | n.a. |
| Q3 2022 | 5 | $1.2bn | n.a. | n.a. |
| Q4 2022 | 6 | $2.1bn | n.a. | n.a. |
| Q1 2023 | 7 | $1.8bn | n.a. | n.a. |
| Q2 2023 | 6 | $1.5bn | n.a. | n.a. |
| Q3 2023 | 4 | $1.7bn | n.a. | n.a. |
| Q4 2023 | 2 | $1.0bn | 1 | 1 |
| Q1 2024 | 4 | $926m | 3 | 1 |
| Q2 2024 | 7 | $949m | 6 | 1 |
| Q3 2024 | 7 | $1.6bn | 5 | 2 |
| Q4 2024 | 4 | $1.3bn | 2 | 2 |
| Q1 2025 | 14 | $3.4bn | 12 | 2 |
| Q2 2025 | 6 | $1.3bn | 2 | 7 |
| Q3 2025 | 8 | $2.1bn | 4 | 3 |
| Q4 2025 | 9 | $1.8bn | 15 | 8 |
| Q1 2026 | 9 | $2.1bn | 19 | 8 |
| Q2 2026 | 12 | $2.5bn | 16 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ONC and LLY →ONC and JNJ →ONC and VRTX →Choose a stock to compare with ONC →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ONC, latest filings →Back to the 13F Explorer →